combivir

Generic: lamivudine and zidovudine

Labeler: viiv healthcare company
NDC Directory HUMAN PRESCRIPTION DRUG NDA Inactive Finished

Drug Facts

Product Profile

Brand Name combivir
Generic Name lamivudine and zidovudine
Labeler viiv healthcare company
Dosage Form TABLET, FILM COATED
Routes
ORAL
Active Ingredients

lamivudine 150 mg/1, zidovudine 300 mg/1

Manufacturer
ViiV Healthcare Company

Identifiers & Regulatory

Product NDC 49702-202
Product ID 49702-202_42a6587e-9322-4810-8c72-1dc40f3543d2
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category NDA
Application Number NDA020857
Marketing Start 2010-10-19
Marketing End 2027-02-28

Pharmacologic Class

Established (EPC)
hepatitis b virus nucleoside analog reverse transcriptase inhibitor [epc] human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor [epc]
Mechanism of Action
nucleoside reverse transcriptase inhibitors [moa]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 49702202
Hyphenated Format 49702-202

Supplemental Identifiers

RxCUI
200082 213088
UPC
0349702202184
UNII
2T8Q726O95 4B9XT59T7S
NUI
N0000175656 N0000175462 N0000009947

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name combivir (source: ndc)
Generic Name lamivudine and zidovudine (source: ndc)
Application Number NDA020857 (source: ndc)
Routes
ORAL
source: ndc

Resolved Composition

Strengths
  • 150 mg/1
  • 300 mg/1
source: ndc
Packaging
  • 60 TABLET, FILM COATED in 1 BOTTLE (49702-202-18)
source: ndc

Packages (1)

49702-202-18 60 TABLET, FILM COATED in 1 BOTTLE (49702-202-18)

Ingredients (2)

lamivudine (150 mg/1) zidovudine (300 mg/1)

Linked Drug Pages (1)

COMBIVIR ndc-match (0.9)

Raw FDA Data

View complete raw FDA NDC JSON payload 
{"route": ["ORAL"], "spl_id": "42a6587e-9322-4810-8c72-1dc40f3543d2", "openfda": {"nui": ["N0000175656", "N0000175462", "N0000009947"], "upc": ["0349702202184"], "unii": ["2T8Q726O95", "4B9XT59T7S"], "rxcui": ["200082", "213088"], "spl_set_id": ["16da660b-9981-4d24-a14a-94c7744fce4f"], "pharm_class_epc": ["Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"], "pharm_class_moa": ["Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "manufacturer_name": ["ViiV Healthcare Company"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "60 TABLET, FILM COATED in 1 BOTTLE (49702-202-18)", "package_ndc": "49702-202-18", "marketing_end_date": "20270228", "marketing_start_date": "20101019"}], "brand_name": "COMBIVIR", "product_id": "49702-202_42a6587e-9322-4810-8c72-1dc40f3543d2", "dosage_form": "TABLET, FILM COATED", "pharm_class": ["Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "product_ndc": "49702-202", "generic_name": "lamivudine and zidovudine", "labeler_name": "ViiV Healthcare Company", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "COMBIVIR", "active_ingredients": [{"name": "LAMIVUDINE", "strength": "150 mg/1"}, {"name": "ZIDOVUDINE", "strength": "300 mg/1"}], "application_number": "NDA020857", "marketing_category": "NDA", "marketing_end_date": "20270228", "marketing_start_date": "20101019"}